Platelet Transfusion in Acute Intracerebral Hemorrhage

Platelet Transfusion in Acute Primary Intracerebral Hemorrhage for Patients on Platelet Inhibitors

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00699621

Enrollment

100

Registered

2008-06-18

Start date

2009-01-31

Completion date

2014-12-31

Last updated

2010-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral Hemorrhage

Keywords

Intracerebral hemorrhage, Hematoma enlargement, Antiplatelet agent, Platelet transfusion, Outcome

Brief summary

* To prove whether use of antiplatelet agents results into a rapid enlargement of hematoma after onset of acute intracerebral hemorrhage. * To prove the efficacy and safety of platelet transfusion for prevention of hematoma growth in patients who were stricken by acute intracerebral hemorrhage while being on antiplatelet medication.

Detailed description

* Hematoma growth is a well-known powerful determinant of mortality and poor outcome after intracerebral hemorrhage. * Some observations suggest that previous use of antiplatelet agents associates with rapid hematoma enlargement and poor outcome after cerebral hemorrhage. * Immediate platelet transfusion for such patients may prevent hematoma growth but also cause thromboembolic complications.

Interventions

BIOLOGICALplatelets

Four units of fresh platelets will be infused immediately

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* being on either aspirin or clopidogrel or a combination of aspirin and dipyridamole * acute primary ICH * \> 17 years * admitted within 6 h after onset of ICH * ICH score \< 4

Exclusion criteria

* other type of ICH than acute primary intracerebral hemorrhage * patients who need neurosurgery * life expectancy less than 3 months due to comorbid disorders * confirmed malignant disease (cancer) * confirmed acute myocardial infarction * hepatitis and/liver cirrhosis * renal failure * infectious disease (HIV, endocarditis etc.) * current or previous hematologic disease * women of childbearing age if pregnant * participation in another study within the preceding 30 days

Design outcomes

Primary

Measure	Time frame
Hematoma growth within 24 h measured as increase in hematoma volume observed by head CT	24 hours

Secondary

Measure	Time frame
Glasgow Outcome Score	90 days
Cardiovascular death occurring within the treatment period	90 days
Death due to any cause occurring within the treatment period	90 days
Acute myocardial infarction	90 days
Venous thromboembolism	90 days

Countries

Finland

Contacts

Primary ContactMatti E Hillbom, MD, PhD

matti.hillbom@oulu.fi358-8-315-4518

Backup ContactJuha T Huhtakangas, MD

juha.huhtakangas@ppshp.fi358-8-315-4032

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026